ADC Therapeutics (ADCT) Q4 2025 earnings summary

Executive summary

• Strategic focus on ZYNLONTA, discontinuing non-core solid tumor programs and reprioritizing resources to hematologic malignancies, with lifecycle management and advancement of LOTIS-5 and LOTIS-7 studies and IITs in indolent lymphomas.

• Operating cost structure reduced by ~50% since 2022, with a strengthened balance sheet through ~$350M in proceeds from equity and business development activities.

• Commercial execution maintained ZYNLONTA's market position in third-line plus DLBCL despite new competition, with stable sales and a Q4 rebound after a low Q3.

• Cash and cash equivalents stood at $261.3M as of December 31, 2025, providing an expected runway at least into 2028.

• Upgraded management team, executed a ~30% global workforce reduction, and closed UK operations as part of strategic restructuring.

Financial highlights

• Q4 2025 net product revenues were $22.3M, up from $16.4M in Q4 2024 (36.2% YoY growth); full year 2025 net product revenues reached $73.6M, compared to $69.3M in 2024.

• Net loss for Q4 2025 was $6.4M ($0.04/share), improved from $30.7M ($0.29/share) in Q4 2024; full year net loss was $142.6M ($1.12/share), down from $157.8M ($1.62/share) in 2024.

• Adjusted net loss for 2025 was $91.7M ($0.72/share), down from $111.4M ($1.15/share) in 2024.

• Q4 operating expenses were $41M (GAAP) and $39.4M (non-GAAP); full year operating expenses were $202.9M (GAAP) and $181.3M (non-GAAP), both lower year-over-year.

• R&D expenses decreased to $104.0M in 2025 from $109.6M in 2024, reflecting reduced spending on discontinued programs.

Outlook and guidance

• Expectation to share LOTIS-5 top-line data in Q2 2026, with full results by year-end and potential FDA submission or compendia inclusion in 2027.

• LOTIS-7 full data expected by end of 2026, with regulatory pathway assessment in 1H 2027; indolent lymphoma data to be published between late 2026 and mid-2027.

• R&D expenses projected to decline in 2026 and 2027 as trials wind down.

• Cash runway expected at least into 2028, supporting current trials, pre-launch activities, and long-term growth initiatives.